SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines. Learn more.

Contact Us

Get in Touch

Whether you’re interested in partnering on our ultrasound-mediated approach, investing in SonoThera, or exploring your next career, we’d love to hear from you.

"*" indicates required fields